GlobeNewswire by notified

Karolinska Development's portfolio company OssDsign enrolls the first patient to the multi-center registry PROPEL

Share

STOCKHOLM, SWEDEN, April 4, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company OssDsign has enrolled the first patient to the company’s multi-center, prospektive spinal fusion registry in the U.S, PROPEL. The objective is to evaluate the use and outcome of OssDsign Catalyst in real-world clinical practice.

OssDsign has initiated a patient registry for spinal fusion that initially will evaluate the rate of fusion, twelve months following treatment with the company’s nanosynthetic bone graft, OssDsign Catalyst. The product received FDA clearance in 2020 and was launched on the U.S. market in August 2021.

"The PROPEL registry will provide OssDsign with important data and serve as base for an ongoing dialogue with surgeons in the U.S., which will have a significant impact on the company’s ongoing launch of OssDsign Catalyst in the U.S. market,” says Viktor Drvota, CEO, Karolinska Development.

Karolinska Development's shareholding in OssDsign AB, including an indirect ownership via KCIF Co-Investment Fund, amounts to 10.4 per cent.

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: johan.dighed@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Cool Company Ltd. – Q1 2022 Business Update call16.5.2022 23:04:27 CEST | Press release

Cool Company Ltd will hold a Q1 2022 business update call for investors at 10am Oslo time on Tuesday May 31. Prior to the start of the call a presentation will be made available in the Investors section of the Cool Company Ltd. website www.coolcoltd.com We recommend that participants join the conference call via the listen-only live webcast link provided. Sell-side analysts interested in raising a question during the Q&A session that will immediately follow the presentation should access the event via the conference call dial-in information below. Please dial in 10 minutes prior to the start time to allow time for call handling. Information on how to ask questions will be given at the beginning of the Q&A session. There will be a limit of two questions per participant. a. Listen-only live webcastlink Go to the Investors section at www.coolcoltd.com and click on the link to "Webcast". To listen to the conference call from the web, you need to have installed Windows Media Player, and you

Golar releases its 2021 Environmental, Social and Governance report16.5.2022 22:53:05 CEST | Press release

Golar LNG Limited (“Golar”) is pleased to announce that it has issued its 2021 Environmental, Social and Governance (“ESG”) report. This comprehensive report describes Golar’s important role in advancing the global energy transition to a lower carbon future - championing LNG as a transition fuel in partnership with renewables, and as a reliable alternative for those in need of energy security today. As part of our target to further reduce emissions from our operations Golar has invested in a carbon capture technology company that has developed and achieved proof of concept for a CO2 capture and separation membrane technology. Subject to successful completion of a commercial pilot project with another industrial user, the technology could be used in future FLNG projects. Our 2021 ESG report is attached and will also be posted to our website. Forward-Looking Statements This press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934

Inventiva reports 2022 First Quarter Financial Information and provides clinical development update16.5.2022 22:00:00 CEST | Press release

Cash position2 at €80.5m as of March 31, 2022The Group did not generate any revenue in Q1 2022Signature of a €50 million bullet credit facility agreement with the European Investment BankUpdate on lanifibranor recruitment timing for Phase III trial in patients with NASH, as well as for the two Phase II trials in patients with NAFLD and type 2 diabetes, and in combination with empagliflozine Daix (France), Long Island City (New York, United States), May 16, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today reported its cash position as of March 31, 2022 and its revenues for the first quarter of 20221, and provided an update on its clinical programs. Cash Position As of March 31, 2022, Inventiva’s cash position stood at €80.5 million com

ASM INTERNATIONAL N.V. ANNOUNCES VOTING RESULTS OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS16.5.2022 21:00:00 CEST | Press release

Almere, the Netherlands May 16, 2022 ASM International N.V. (Euronext Amsterdam: ASM) today announces the voting results of its Annual General Meeting of Shareholders held on May 16, 2022, at the Van der Valk Hotel in Almere, the Netherlands. The shareholders approved all resolutions as proposed to the Annual General Meeting of Shareholders. The main approved resolutions include the following: Mr. Hichem M’Saad was appointed as a member of the Management Board and as the CTO. The Remuneration Policy for the Management Board and for the Supervisory Board were approved. Also Mr. Marc de Jong was reappointed as member of the Supervisory Board. Furthermore the financial statements for the year 2021 were adopted, the shareholders discharged the members of the Management Board and Supervisory Board from liability in relation to the exercise of their duties in the financial year 2021, and the shareholders also voted in favor of a regular dividend payment of €2.50 per common share. About ASM I

Electra Gruppen AB (publ) (u.ä.t Elon AB (publ)) offentliggör prospekt avseende upptagande till handel av nyemitterade aktier på Nasdaq Stockholm i samband med apportemission16.5.2022 18:00:00 CEST | Pressemelding

ELECTRA GRUPPEN AB (publ) orgnr. 556065-4054 Pressmeddelande 2022-05-16 Electra Gruppen AB (publ) (u.ä.t Elon AB (publ)) offentliggör prospekt avseende upptagande till handel av nyemitterade aktier på Nasdaq Stockholm i samband med apportemission Electra Gruppen AB (publ) (u.ä.t Elon AB (publ)) (”Electra” eller ”Bolaget”), offentliggör idag det prospekt som upprättats inför upptagande till handel av de nyemitterade aktierna på Nasdaq Stockholm med anledning av den apportemission genom vilken Electra förvärvar samtliga aktier i Elon Group AB (”Elon”) (”Transaktionen”). Transaktionen beskrivs närmare i Electras pressmeddelande daterat den 7 december 2021. På Electras årsstämma den 28 mars 2022 bemyndigades styrelsen att besluta om apportemissionen för att genomföra Transaktionen. Den 13 maj 2022 beslutade Electras styrelse om apportemission av 9 659 223 aktier till Elon Group Holding. Prospektet som har upprättats med anledning av upptagande till handel av de nyemitterade aktierna i samb